Fixed drug eruption in a patient of HLA‐B58:01 negative after allopurinol administration: A case report
What is known and objective Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced CADRs, especially for Asian descents....
Gespeichert in:
Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2022-06, Vol.47 (6), p.841-843 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 843 |
---|---|
container_issue | 6 |
container_start_page | 841 |
container_title | Journal of clinical pharmacy and therapeutics |
container_volume | 47 |
creator | Zhang, Ruiqi Geng, Hui Du, Jiali Liu, Meilin |
description | What is known and objective
Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced CADRs, especially for Asian descents.
Case summary
A 60‐year‐old Chinese Han male patient took allopurinol for lowering uric acid after the negative result from HLA‐B*58:01 testing. Then, he experienced episodes of well‐demarcated pruritic erythematous patches on the whole body that developed into blisters and pustular eruption. Fixed drug eruption (FDE) was diagnosed by skin biopsy and improved with withdrawal and hormone treatments.
What is new and conclusion
It should be kept in mind that cutaneous drug eruption might occur after allopurinol administration in Asians of HLA‐B*58:01 negative. Awareness among medical practitioners about FDE can lead to correct diagnosis, treatment and decreased damage as well as lower therapeutic costs.
HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced cutaneous adverse drug reactions, especially for Asian descents. We present a case of a Chinese Han male of HLA‐B*58:01 negative who developed fixed drug eruption after the administration of allopurinol for the first time. |
doi_str_mv | 10.1111/jcpt.13616 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2676761901</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2676761901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3606-70102df769188624fd54f8e8a7c38aeb21d4f27005bf6c6ea21c05a0c4bde5f73</originalsourceid><addsrcrecordid>eNp9kLFOwzAQhi0EoqWw8ADIEhtSis9JbLdbqSgFVYKhzJGTnCtXaRKcBOjGI_CMPAkpKYzcDf9wn76TfkLOgQ2hnet1UtZD8AWIA9JvM_S4BHZI-oyLkRdILnvkpKrWjDEhuX9Men4IoISCPrEz-44pTV2zouiasrZFTm1ONS11bTGvaWHofDH5-vi8CdWYAc1x1V5ekWpTo6M6y4qycTYvMqrTjc1tVTu904zphCa6QuqwLFx9So6Mzio82-eAPM9ul9O5t3i8u59OFl7iCyY8yYDx1EgxAqUED0waBkah0jLxlcaYQxoYLhkLYyMSgZpDwkLNkiBOMTTSH5DLzlu64qXBqo7WRePy9mXEhWwXRgxa6qqjEldUlUMTlc5utNtGwKJdq9Gu1ein1Ra-2CubeIPpH_pbYwtAB7zZDLf_qKKH6dOyk34Dq8SCWA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2676761901</pqid></control><display><type>article</type><title>Fixed drug eruption in a patient of HLA‐B58:01 negative after allopurinol administration: A case report</title><source>Access via Wiley Online Library</source><creator>Zhang, Ruiqi ; Geng, Hui ; Du, Jiali ; Liu, Meilin</creator><creatorcontrib>Zhang, Ruiqi ; Geng, Hui ; Du, Jiali ; Liu, Meilin</creatorcontrib><description>What is known and objective
Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced CADRs, especially for Asian descents.
Case summary
A 60‐year‐old Chinese Han male patient took allopurinol for lowering uric acid after the negative result from HLA‐B*58:01 testing. Then, he experienced episodes of well‐demarcated pruritic erythematous patches on the whole body that developed into blisters and pustular eruption. Fixed drug eruption (FDE) was diagnosed by skin biopsy and improved with withdrawal and hormone treatments.
What is new and conclusion
It should be kept in mind that cutaneous drug eruption might occur after allopurinol administration in Asians of HLA‐B*58:01 negative. Awareness among medical practitioners about FDE can lead to correct diagnosis, treatment and decreased damage as well as lower therapeutic costs.
HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced cutaneous adverse drug reactions, especially for Asian descents. We present a case of a Chinese Han male of HLA‐B*58:01 negative who developed fixed drug eruption after the administration of allopurinol for the first time.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.13616</identifier><identifier>PMID: 35118681</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Allopurinol ; Arthritis ; Biopsy ; Case reports ; fixed drug eruption ; Genetic markers ; Histocompatibility antigen HLA ; HLA genotyping ; Hyperuricemia ; Patients ; Skin eruptions ; Uric acid</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2022-06, Vol.47 (6), p.841-843</ispartof><rights>2022 John Wiley & Sons Ltd.</rights><rights>Copyright © 2022 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3606-70102df769188624fd54f8e8a7c38aeb21d4f27005bf6c6ea21c05a0c4bde5f73</citedby><cites>FETCH-LOGICAL-c3606-70102df769188624fd54f8e8a7c38aeb21d4f27005bf6c6ea21c05a0c4bde5f73</cites><orcidid>0000-0001-7137-7807</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.13616$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.13616$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35118681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Ruiqi</creatorcontrib><creatorcontrib>Geng, Hui</creatorcontrib><creatorcontrib>Du, Jiali</creatorcontrib><creatorcontrib>Liu, Meilin</creatorcontrib><title>Fixed drug eruption in a patient of HLA‐B58:01 negative after allopurinol administration: A case report</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>What is known and objective
Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced CADRs, especially for Asian descents.
Case summary
A 60‐year‐old Chinese Han male patient took allopurinol for lowering uric acid after the negative result from HLA‐B*58:01 testing. Then, he experienced episodes of well‐demarcated pruritic erythematous patches on the whole body that developed into blisters and pustular eruption. Fixed drug eruption (FDE) was diagnosed by skin biopsy and improved with withdrawal and hormone treatments.
What is new and conclusion
It should be kept in mind that cutaneous drug eruption might occur after allopurinol administration in Asians of HLA‐B*58:01 negative. Awareness among medical practitioners about FDE can lead to correct diagnosis, treatment and decreased damage as well as lower therapeutic costs.
HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced cutaneous adverse drug reactions, especially for Asian descents. We present a case of a Chinese Han male of HLA‐B*58:01 negative who developed fixed drug eruption after the administration of allopurinol for the first time.</description><subject>Allopurinol</subject><subject>Arthritis</subject><subject>Biopsy</subject><subject>Case reports</subject><subject>fixed drug eruption</subject><subject>Genetic markers</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA genotyping</subject><subject>Hyperuricemia</subject><subject>Patients</subject><subject>Skin eruptions</subject><subject>Uric acid</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kLFOwzAQhi0EoqWw8ADIEhtSis9JbLdbqSgFVYKhzJGTnCtXaRKcBOjGI_CMPAkpKYzcDf9wn76TfkLOgQ2hnet1UtZD8AWIA9JvM_S4BHZI-oyLkRdILnvkpKrWjDEhuX9Men4IoISCPrEz-44pTV2zouiasrZFTm1ONS11bTGvaWHofDH5-vi8CdWYAc1x1V5ekWpTo6M6y4qycTYvMqrTjc1tVTu904zphCa6QuqwLFx9So6Mzio82-eAPM9ul9O5t3i8u59OFl7iCyY8yYDx1EgxAqUED0waBkah0jLxlcaYQxoYLhkLYyMSgZpDwkLNkiBOMTTSH5DLzlu64qXBqo7WRePy9mXEhWwXRgxa6qqjEldUlUMTlc5utNtGwKJdq9Gu1ein1Ra-2CubeIPpH_pbYwtAB7zZDLf_qKKH6dOyk34Dq8SCWA</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Zhang, Ruiqi</creator><creator>Geng, Hui</creator><creator>Du, Jiali</creator><creator>Liu, Meilin</creator><general>Hindawi Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><orcidid>https://orcid.org/0000-0001-7137-7807</orcidid></search><sort><creationdate>202206</creationdate><title>Fixed drug eruption in a patient of HLA‐B58:01 negative after allopurinol administration: A case report</title><author>Zhang, Ruiqi ; Geng, Hui ; Du, Jiali ; Liu, Meilin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3606-70102df769188624fd54f8e8a7c38aeb21d4f27005bf6c6ea21c05a0c4bde5f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Allopurinol</topic><topic>Arthritis</topic><topic>Biopsy</topic><topic>Case reports</topic><topic>fixed drug eruption</topic><topic>Genetic markers</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA genotyping</topic><topic>Hyperuricemia</topic><topic>Patients</topic><topic>Skin eruptions</topic><topic>Uric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Ruiqi</creatorcontrib><creatorcontrib>Geng, Hui</creatorcontrib><creatorcontrib>Du, Jiali</creatorcontrib><creatorcontrib>Liu, Meilin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Ruiqi</au><au>Geng, Hui</au><au>Du, Jiali</au><au>Liu, Meilin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fixed drug eruption in a patient of HLA‐B58:01 negative after allopurinol administration: A case report</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2022-06</date><risdate>2022</risdate><volume>47</volume><issue>6</issue><spage>841</spage><epage>843</epage><pages>841-843</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract>What is known and objective
Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced CADRs, especially for Asian descents.
Case summary
A 60‐year‐old Chinese Han male patient took allopurinol for lowering uric acid after the negative result from HLA‐B*58:01 testing. Then, he experienced episodes of well‐demarcated pruritic erythematous patches on the whole body that developed into blisters and pustular eruption. Fixed drug eruption (FDE) was diagnosed by skin biopsy and improved with withdrawal and hormone treatments.
What is new and conclusion
It should be kept in mind that cutaneous drug eruption might occur after allopurinol administration in Asians of HLA‐B*58:01 negative. Awareness among medical practitioners about FDE can lead to correct diagnosis, treatment and decreased damage as well as lower therapeutic costs.
HLA‐B*58:01 is a highly specific and effective genetic marker for the detection of allopurinol‐induced cutaneous adverse drug reactions, especially for Asian descents. We present a case of a Chinese Han male of HLA‐B*58:01 negative who developed fixed drug eruption after the administration of allopurinol for the first time.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>35118681</pmid><doi>10.1111/jcpt.13616</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7137-7807</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-4727 |
ispartof | Journal of clinical pharmacy and therapeutics, 2022-06, Vol.47 (6), p.841-843 |
issn | 0269-4727 1365-2710 |
language | eng |
recordid | cdi_proquest_journals_2676761901 |
source | Access via Wiley Online Library |
subjects | Allopurinol Arthritis Biopsy Case reports fixed drug eruption Genetic markers Histocompatibility antigen HLA HLA genotyping Hyperuricemia Patients Skin eruptions Uric acid |
title | Fixed drug eruption in a patient of HLA‐B58:01 negative after allopurinol administration: A case report |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A14%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fixed%20drug%20eruption%20in%20a%20patient%20of%20HLA%E2%80%90B58:01%20negative%20after%20allopurinol%20administration:%20A%20case%20report&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Zhang,%20Ruiqi&rft.date=2022-06&rft.volume=47&rft.issue=6&rft.spage=841&rft.epage=843&rft.pages=841-843&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1111/jcpt.13616&rft_dat=%3Cproquest_cross%3E2676761901%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2676761901&rft_id=info:pmid/35118681&rfr_iscdi=true |